A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma

BACKGROUND: Perioperative chemotherapy/chemoradiation is standard in esophageal/gastric/gastroesophageal junction (GEJ) adenocarcinoma, immune checkpoint inhibitors (ICI) effect in setting of metastatic and postoperatively. This study is to assess ICI + chemotherapy perioperatively. METHODS: Patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Weijing, Veeramachaneni, Nirmal, Al‐Rajabi, Raed, Madan, Rashna, Kasi, Anup, Al‐Kasspooles, Mazin, Baranda, Joaquina, Saeed, Anwaar, Phadnis, Milind A., Godwin, Andrew K., Olyaee, Mojtaba, Streeter, Natalie, Nagji, Alykhan, Dai, Junqiang, Williamson, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469814/
https://www.ncbi.nlm.nih.gov/pubmed/37326317
http://dx.doi.org/10.1002/cam4.6263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469814/
https://www.ncbi.nlm.nih.gov/pubmed/37326317
http://dx.doi.org/10.1002/cam4.6263

Ejemplares similares